SUZHOU, China and MÖLNDAL, Sweden, Feb. 11, 2026 /PRNewswire/ -- Suzhou Ribo Life Science Co., Ltd. (HKEX: 06938) ("Ribo") and its subsidiary Ribocure Pharmaceuticals AB ("Ribocure") today announced that they have entered into an exclusive worldwide licensing agreement with Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) ("Madrigal") for six pre-clinical small interfering RNA (siRNA) programs for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). The collaboration will utili

February 10, 2026. Sanofi today announced that it has completed the acquisition of Dynavax Technologies Corporation (Dynavax). The acquisition includes Dynavax’s adult hepatitis B vaccine HEPLISAV-B, which is currently marketed in the US and is differentiated by its two-dose regimen over one month. It also includes Dynavax’s shingles vaccine candidate (Z-1018), which is currently in phase 1/2 studies, and additional vaccine pipeline projects. This acquisition augments Sanofi’s presence in adult

Upstream Bio on Wednesday said its TSLP-targeting drug met its goal in a mid-stage trial in severe asthma, which is a step forward in its bid to challenge Dupixent and Tezspire down the line. The biotech’s verekitug, given at a 100 mg dose every three months, reduced the rate of yearly asthma flare-ups by 56% versus placebo in the study’s primary endpoint. The result was statistically significant, with a p-value of less than 0.0003. In the less frequent regimen, a 400 mg dose once every six mont

HONG KONG, Feb. 11, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) is pleased to announce that the National Medical Products Administration has approved the initiation of Phase II clinical trials for AK139, a first-in-class IL-4Rα/ST2-targeting bispecific antibody, across seven indications. These indications include chronic obstructive pulmonary disease (COPD), severe bronchial asthma, chronic spontaneous urticaria, allergic rhinitis, chronic rhinosinusitis with nasal polyps, moderate-to-severe ato

CAMBRIDGE, Mass., Feb. 10, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico", 03696.HK), a clinical-stage biotechnology company driven by generative artificial intelligence (AI), China Medical System Holdings Limited ("CMS", 867.HK/8A8.SG), an open-platform innovative company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, today announced a series of AI‑empowered drug discovery collaborations across multiple projects in the fields of

TAINAN, Feb. 9, 2026 /PRNewswire/ -- MerryLife Biomedical Inc., a clinical-stage biotechnology company focused on neurodegenerative diseases, today announced positive Phase 1 results for TML-6, its investigational oral therapy for Alzheimer's disease (AD). The study demonstrated that TML-6 was generally well tolerated with a favorable safety profile, supporting its continued clinical development. TML-6 is designed to modulate the autolysosomal system and interconnected cellular pathways involved

Financing led by Investissement Qu é bec with continued support from long-standing investors Plans include the acceleration of clinical development of breakthrough GPCR targeting treatments for patients MONTREAL and STRASBOURG, France and BOSTON, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Kainova Therapeutics (“the Company”), a key player for breakthrough treatments for patients in immuno-oncology and inflammation, today announced the successful first close of its Series B financing round totaling $32 mi

This FDA Acceptance is a Milestone for People Living with Narcolepsy Type 1 Who Need New and Different Treatment Options Oveporexton is an Orexin Agonist Designed to Restore Orexin Signaling and Address the Underlying Orexin Deficiency that Causes Narcolepsy Type 1 The Prescription Drug User Fee Act (PDUFA) Target Action Date is the Third Quarter of this Calendar Year OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda ( TSE:4502/NYSE:TAK ) today announced that the U.S. Food and Drug Admini

Diseases Cause Damage in Some of the Same Ways NEW YORK, Feb. 10, 2026 /PRNewswire/ -- The increased size of, and lesser blood supply to, a key brain structure in patients with Long COVID tracks with known blood markers of Alzheimer's disease and greater levels of dementia, a new study finds. Led by NYU Langone Health researchers, the study concerns the choroid plexus (CP), a network of blood vessels lined by cells that produce cerebrospinal fluid, which cushions the brain and forms a protective

Pfizer joins six leading pharma companies helping launch and grow exceptional biotech ventures. BASEL, Switzerland, Feb. 10, 2026 /PRNewswire/ -- BaseLaunch, a platform partnering with scientists and entrepreneurs to launch, fund, and build early biotech ventures, announced today the pharmaceutical giant Pfizer has joined the Basel-based incubator, bringing the total number of leading pharma company partners to seven. Continue Reading Landscape image of the Basel area’s booming biotech research